TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia
DRUG: TGR-1202 + Obinutuzumab + Chlorambucil
Maximum Tolerated Dose acceptable for participants, To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities, 28 days (1 cycle of therapy)
Overall Response Rate, To assess the overall response rate (ORR) in patients with chronic lymphocytic leukemia treated with TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil, Up to 1 year
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.